Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6 –Cyclin D–Rb pathway
ConclusionsOur pre-clinical evidence provides a rationale of initializing clinical trial of investigating the efficacy of abemaciclib in combination with doxorubicin in osteosarcoma patients. Our work also highlights the therapeutic value of CDK4/6 inhibition in osteosarcoma with proper function of Rb.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Bone Cancers | Breast Cancer | Cancer | Cancer & Oncology | Cancer in Adolescents | Chemotherapy | Children | Clinical Trials | Drugs & Pharmacology | Osteosarcoma | Study | Toxicology